Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
Completed · Phase 1 · Has a placebo group
Conditions studied: Alzheimer's Disease
In brief
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered as single doses to healthy adult volunteers and healthy elderly subjects. The study will consist of 2 parts:(1) a single dose in healthy adult volunteers, at doses up to 800 mg or the maximum dose that can be tolerated, (2) a single dose of 50 mg in healthy elderly volunteers.
Key facts
- Study ID
- NCT01294540
- Run by
- Eisai Inc.
- People needed
- 73
- Starts
- 2010-12-01
- Expected to finish
- 2011-12-01
- Last updated by the study team
- 2013-08-29
Who can join
Age: 30 and older, up to 85. Sex: any. Healthy volunteers: accepted.
Where it is running
- Glendale Adventist Medical Center — Glendale, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.